U.S. Food and Drug Administration Approves Rituximab (RITUXAN) Plus Chemotherapy for Pediatric B-cell Lymphomas
Rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, has been approved in combination with chemotherapy for pediatric patients 6-18 months with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL).